Optimizing Ligand Valency to Maximize Tendon Accumulation of Peptide-Targeted Nanoparticles
ACS Applied Materials & Interfaces · 2024
DOI: 10.1021/acsami.4c13388 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Emmanuela Adjei-Sowah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Rochester, Rochester, New York 14623, United States. Hauptthemen laut MEDLINE: Tendons, Nanoparticles, Peptides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NIA NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
In many tissues, including musculoskeletal tissues such as tendon, systemic delivery typically results in poor targeting of free drugs. Hence, we previously developed a targeted drug delivery nanoparticle (NP) system for tendon healing, leveraging a tartrate resistant acid phosphatase (TRAP) binding peptide (TBP) ligand. The greatest tendon targeting was observed with NPs functionalized with 30 000 TBP ligands per NP at day 7 during the proliferative healing phase, relative to the inflammatory (day 3) and early remodeling (day 14) phases of healing. Nevertheless, TRAP activity varies throughout healing and, therefore, may offer an opportunity for optimizing temporal therapeutic targeting through multivalent interactions. Hence, in this study, we hypothesized that the ligand density (9000-55,000 TBPs per NP) can optimize tendon accumulation on the basis of variable TRAP levels. The multivalent nanoparticles were loaded with three different fluorophores. In vitro, the ligand density and fluorophore had no effect on the physicochemical properties of the NPs, including size, charge, polydispersity index, or dye loading efficiency; however, the TRAP binding affinity correlated positively with the ligand density. In vivo, the ligand density correlated positively with NP homing and retention in the tendon, establishing opportunities to leverage ligand density for tendon targeting across the tendon healing cascade, during aging, and in other tendon pathologies, including tendinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Rochester, Rochester, New York 14623, United States.
- Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, United States.
- Department of Bioengineering, Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, Oregon 97403, United States.
- Department of Orthopedics & Physical Performance, University of Rochester Medical Center, Rochester, New York 14642, United States.
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, United States.
ORCID-Profile: Alayna E Loiselle, Danielle S W Benoit
Förderung
- NIDCR NIH HHS
- NIA NIH HHS
- NIAMS NIH HHS
- NCRR NIH HHS
- NIH HHS
- National Center for Research Resources
- National Institute on Aging
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Adjei-Sowah, E., Rangasami, V., Loiselle, A. E., & Benoit, D. S. W. (2024). Optimizing Ligand Valency to Maximize Tendon Accumulation of Peptide-Targeted Nanoparticles. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c13388
Vancouver
Adjei-Sowah E, Rangasami V, Loiselle AE, Benoit DSW. Optimizing Ligand Valency to Maximize Tendon Accumulation of Peptide-Targeted Nanoparticles. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c13388
BibTeX
@article{AdjeiSowah2024,
author = {Adjei-Sowah, Emmanuela and Rangasami, Vigneshkumar and Loiselle, Alayna E and Benoit, Danielle S W},
title = {Optimizing Ligand Valency to Maximize Tendon Accumulation of Peptide-Targeted Nanoparticles},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
doi = {10.1021/acsami.4c13388}
}
EUVIMED